Capricor Therapeutics (CAPR) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Capricor Therapeutics (CAPR) over the last 9 years, with Q3 2025 value amounting to -$0.54.
- Capricor Therapeutics' EPS (Weighted Average and Diluted) fell 4210.53% to -$0.54 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6, marking a year-over-year decrease of 5686.27%. This contributed to the annual value of -$1.15 for FY2024, which is 3807.68% down from last year.
- According to the latest figures from Q3 2025, Capricor Therapeutics' EPS (Weighted Average and Diluted) is -$0.54, which was down 4210.53% from -$0.57 recorded in Q2 2025.
- Over the past 5 years, Capricor Therapeutics' EPS (Weighted Average and Diluted) peaked at $0.02 during Q4 2023, and registered a low of -$0.57 during Q2 2025.
- For the 5-year period, Capricor Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.29, with its median value being -$0.28 (2023).
- In the last 5 years, Capricor Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 10645.16% in 2023 and then plummeted by 109539.21% in 2024.
- Over the past 5 years, Capricor Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.26 in 2021, then fell by 19.23% to -$0.31 in 2022, then soared by 106.45% to $0.02 in 2023, then tumbled by 1095.39% to -$0.2 in 2024, then crashed by 171.25% to -$0.54 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.54 for Q3 2025, versus -$0.57 for Q2 2025 and -$0.2 for Q4 2024.